Print

Ipsen (IPN.PA) and Inspiration Biopharmaceuticals Announce That OBI-1 Has Received Fast Track Designation From FDA for Acquired Hemophilia A  
11/20/2012 9:01:51 AM

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN, ADR: IPSEY) (Paris:IPN) and Inspiration Biopharmaceuticals Inc. (Inspiration) today announced that Inspiration has received Fast Track designation from the US Food and Drug Administration (FDA) for OBI-1 in acquired hemophilia A. OBI-1, an intravenous recombinant porcine factor VIII (FVIII), is being evaluated for the treatment of individuals with acquired hemophilia A, who have developed inhibitory antibodies (inhibitors) against their innate FVIII. Fast track is a designation that the FDA reserves for a drug intended to treat a serious disease and has a potential to fill an unmet medical need. Fast track designation is designed to facilitate the development and expedite the review of new drugs. Marketing applications for fast track development programs are likely to be considered appropriate for priority review, which implies an abbreviated review time of eight months. Inspiration intends to submit a biologics license application (BLA) to FDA in the first half of 2013.
//-->